Search Results
Your search for Chase Doyle ,Chase Doyle matches 550 pages
Showing 501 - 550Online Symptom-Management Curriculum May Improve Depression and Fatigue in Breast Cancer Survivors
With thousands of devices to track and manage health and wellness, eHealth tools are beginning to transform modern health care and research, demonstrating quantifiable improvements in patient outcomes. According to the results of a randomized controlled trial (Reimagine), breast cancer survivors...
Expert Point of View: Ann H. Partridge MD, MPH
Ann H. Partridge MD, MPH, Director of Adult Cancer Survivorship Program at the Dana-Farber Cancer Institute, praised the “tremendous work” of Dr. Paskett and her colleagues but referred to the findings as “disappointing to say the least.”1 “Developing interventions to prevent or treat lymphedema...
Search Continues for Effective Way to Prevent Lymphedema in Breast Cancer Survivors
There was no difference in the incidence of lymphedema at 18 months in breast cancer patients randomized to a physical therapy intervention with education materials compared with a control.1 Although poor adherence to the intervention may have been a factor, these results, described as “very...
Expert Point of View: Kevin C. Oeffinger, MD
Kevin C. Oeffinger, MD, Director of the Adult Long-Term Follow-up Program at Memorial Sloan Kettering Cancer Center, New York, highlighted the typical fat distribution of this population while noting the limitations of standard criteria for metabolic syndrome, which include waist circumference....
Platinum Study Finds High Risk of Metabolic Syndrome in Testicular Cancer Survivors
A multicenter study of North American testicular cancer survivors treated with platinum-based chemotherapy has found a high prevalence of metabolic syndrome, a cluster of cardiovascular risk factors that doubles the risk of cardiovascular disease.1 According to the results of this trial,...
Expert Point of View: Barry E. Rosenbloom, MD
Moderator of the session, Barry E. Rosenbloom, MD, Clinical Professor of Medicine at Tower Hematology Oncology Medical Group in Los Angeles, said that the overview of recent advances in lung cancer clearly depicts oncology’s state of flux. “There are so many different agents that have been...
New Treatments for Lung Cancer in 2016
With drug approvals for immunotherapy in the first- and second-line settings, breakthroughs in targeting epidermal growth factor receptor (EGFR) mutations, and the rapid evolution of therapies that target anaplastic lymphoma kinase (ALK) rearrangements, 2016 has been an extraordinary year for lung...
Expert Point of View: Steven Piantadosi, MD, PhD
In an interview with The ASCO Post, Steven Piantadosi, MD, PhD, Professor of Medicine and Director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai in Los Angeles, expressed enthusiasm for the Oncology Research Information Exchange Network (ORIEN) network of data-sharing. “With...
Bad Year for Brain Tumors, but Still Reasons for Hope
Checkpoint inhibitors and targeted therapies are reshaping the landscape of cancer care across multiple tumor sites, but treatments for brain tumors remain decidedly unchanged. The standard of care for high-grade gliomas in the front-line setting—a combination of surgery and chemoradiation—is the...
Mutanome-Directed Immunotherapy: Finding the Best Treatment Match
Oncologists may be accustomed to looking for commonalities in patients, but highly personalized therapies are now being developed based on mutational analysis of tumors. According to data presented at the Cedars-Sinai annual symposium on New Therapeutics in Oncology: The Road to Personalized...
Expert Point of View: Michael O. Koch, MD
Session moderator, Michael O. Koch, MD, Professor of Urology and Chairman of the Department of Urology at Indiana University School of Medicine, Indianapolis, described the drug as a “game-changer for metastatic disease.” “The last [development] that was even similar to this was when the MVAC...
Atezolizumab in Platinum-Treated Advanced Urothelial Carcinoma: A New Standard of Care?
Compared with a historic control rate, a phase II study of the programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab (Tecentriq) has demonstrated clinically meaningful responses in patients with urothelial carcinoma who progressed after platinum-based chemotherapy.1 Hailed as a “major...
Expert Point of View: Sam S. Chang, MD, MBA
Moderator of the session, Sam S. Chang, MD, MBA, Professor of Urologic Surgery at Vanderbilt University Medical Center, Nashville, and American Urological Association spokesperson, said that due to these results he would definitely consider this treatment option for both high-risk and African...
Chemotherapy After Radical Prostatectomy May Benefit African Americans and High-Risk Patients
A new U.S. Department of Veterans Affairs (VA) study suggests that African American men and men with a higher tumor stage may benefit from adjuvant chemotherapy following radical prostatectomy.1 According to prespecified analysis of these two “high–risk” subgroups, patients with ≥ T3b disease had a ...
Breaking Down Dogma With the Outgoing President of SGO
At the 2016 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, The ASCO Post sat down with the SGO’s outgoing President, Robert L. Coleman, MD, and discussed the revolutionary potential of blood biomarkers, why enhanced recovery after surgery protocols is a significant...
Roundup of Ovarian Cancer Abstracts From 2016 SGO Annual Meeting on Women’s Cancer
At the 2016 Society of Gynecologic Oncology’s (SOG’s) Annual Meeting on Women’s Cancer, Thomas J. Herzog, MD, Clinical Director, University of Cincinnati (UC) Cancer Institute and Professor of Obstetrics and Gynecology at UC College of Medicine, provided commentary on several noteworthy ovarian...
Expert Point of View: Gini Fleming, MD
In the discussion session, Gini Fleming, MD, Professor of Medicine and Director of the Gynecologic Oncology and Medical Oncology Breast Program at the University of Chicago Medical Center, analyzed the three previous, large trials on which the presumed benefits of intraperitoneal therapy in women...
Intraperitoneal Chemotherapy in Question in Ovarian Cancers
A phase III trial of bevacizumab (Avastin) with intravenous vs intraperitoneal chemotherapy showed no improvement in progression-free survival for first-line treatment of patients with optimally surgically resected stage II and III ovarian, peritoneal, or fallopian tube cancer.1 When compared with...
Expert Point of View: Douglas A. Levine, MD
In the discussion session, Douglas A. Levine, MD, Head of Gynecology Research Laboratory at Memorial Sloan Kettering Cancer Center, said that while advanced genomics can help to predict outcomes, stratify treatment, and understand biology, one of the problems of precision medicine is that...
Liquid Biopsies Predict Treatment Response and Survival in Gynecologic Cancers
A new study has demonstrated for the first time that personalized circulating tumor DNA (ctDNA) biomarkers in gynecologic cancers can detect the presence of residual tumor earlier than currently used serum and imaging studies.1,2 According to the data, undetectable levels of ctDNA at the completion ...
Expert Point of View: Kian Behbakht, MD
Kian Behbakht, MD, Professor of Gynecologic Oncology at the University of Colorado School of Medicine, Aurora, said that the study underscored the surgical importance of getting to no visible residual disease in ovarian cancer. “Based on today’s data,” said Dr. Behbakht, “it seems as though it’s...
Study Supports Initial Attempt at Debulking Surgery in Stage IIIC Ovarian, Fallopian Tube, and Peritoneal Carcinoma
In a study exploring the effect of primary debulking surgery in women with bulky stage IIIC ovarian, fallopian tube, and primary peritoneal cancers, cytoreduction to no gross residual disease was associated with the best survival outcomes.1 Cytoreduction to 1 to 10 mm of residual disease was also...
Expert Point of View: Kristin Zorn, MD
Kristin Zorn, MD, Associate Professor and Director of Gynecologic Oncology at the University of Arkansas for Medical Sciences, Little Rock, said that the study’s data confirm the importance of other homologous recombination genes in these defects, not just BRCA1 and BRCA2. “I think this really...
Genetic Testing in Women With Ovarian Cancer Helps to Determine Prognosis
A new study suggests that homologous recombination deficiency may have significant prognostic implications for patients with ovarian cancer, highlighting the importance of genetic testing in this population.1 According to the data, patients with ovarian cancer who have mutations in genes affecting...
Expert Point of View: Kathleen Moore, MD
Session moderator Kathleen Moore, MD, Associate Professor of Obstetrics and Gynecology at the University of Oklahoma College of Medicine, Oklahoma City, said that while the response rates are “not incredibly high,” trabectedin offers another line of therapy where there previously was none. “I think ...
Trabectedin Improves Progression-Free Survival in Uterine Leiomyosarcoma
In women with uterine leiomyosarcoma, trabectedin (Yondelis), a novel cytotoxic agent, significantly improved progression-free survival, compared with dacarbazine (4.2 vs 1.5 months, hazard ratio [HR] = 0.55, P < .001). According to the study’s authors, a lack of cumulative toxicity allows...
Survivorship Care in Manitoba: Transition Appointments and Follow-up Care Plans
Working with specialized oncology teams, a provincial agency in Manitoba, Canada, has developed standardized care plans and guidelines for cancer survivors that are implemented in a transition appointment.1 This appointment, which follows the end of active treatment, marks the transfer of medical...
Expert Point of View: Kathryn Schmitz, PhD, MPH
Discussant Kathryn Schmitz, PhD, MPH, Professor of Epidemiology at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, emphasized the compelling body of literature on the efficacy of weight loss and exercise programs for a broad variety of outcomes in the survivorship...
Patient and Provider Engagement With Healthy Lifestyle Information
Most young women diagnosed with breast cancer are not physically active in the months after a cancer diagnosis, but physical activity increased over time. According to data presented at the 2016 Cancer Survivorship Symposium, higher levels of physical activity were seen among women whose oncology...
Expert Point of View: Kathryn Schmitz, PhD, MPH
Discussant Kathryn Schmitz, PhD, MPH, Professor of Epidemiology at the Perelman School of Medicine, University of Pennsylvania, underscored the study’s findings: Diabetes that follows pediatric cancers is not consistent with an autoimmune disorder. “That’s really good news in my book,” said Dr....
Study Finds Abnormal Insulin and Glucose Dynamics in Childhood Survivors Treated With Abdominal Radiation
An ongoing pilot study, designed to assess dynamic indices of insulin and glucose homeostasis in childhood cancer survivors exposed to abdominal radiation, has found a variety of derangements in glucose and insulin homeostasis in this cohort.1 According to an analysis presented at the 2016 Cancer...
Expert Point of View: Kathryn Schmitz, PhD, MPH
Discussant Kathryn Schmitz, PhD, MPH, Professor of Epidemiology at the Perelman School of Medicine, University of Pennsylvania, lauded the researchers’ successful intervention in what can be a challenging setting. “Dr. Yung presented evidence that it is feasible to conduct an evidence-based,...
Clinic-Based Weight-Loss Intervention Successful in Cancer Survivors
A randomized clinical trial examining the effect of a 15-week healthy living program on weight loss in cancer survivors showed a 5.3% decrease in baseline body weight in those participating in the program.1 “Cancer survivors randomized to a 15-week clinic-based weight-loss intervention lost an...
Detection of Thyroid Cancer Most Cost-Effective With Physical Examination, Not Ultrasound Screening
A study evaluating annual physical examination as a screening method to detect thyroid cancer in cancer survivors exposed to neck radiation has shown a substantial cost reduction compared with ultrasound screening, with no thyroid cancer–related mortality.1 According to the analysis, this method...
Expert Point of View: Chunkit Fung, MD, MSCE
Co-Chair and moderator of the session, Chunkit Fung, MD, MSCE, Assistant Professor at the Wilmot Cancer Center of the University of Rochester in New York, underscored the issue of oversurveillance and patients’ reluctance to adopt a less-is-more philosophy of health care. “Talking to patients about ...
Surveillance for Recurrence and Second Cancers: Guidelines and Caveats
Striking the right balance between under- and oversurveillance of cancer survivors is challenging, and oncology providers are best served by knowing and following guidelines—though they can change often. Cancer recurrence and second cancers are two of the major threats to the health of cancer...
The Value Proposition in Oncology: ASCO Session Weighs Points of View
The value proposition in health care is often represented with the following equation: Value = Outcomes/Cost. The simplicity of this equation, however, belies the complexity of its parts, which are the contributions of multiple stakeholders with unique perspectives. A session presented at the 2015...
MRI Improves Breast Cancer Detection in Women at Average Risk
Magnetic resonance imaging (MRI) screening of women at average risk for breast cancer achieved a mean additional cancer yield of 15.8 cases per 1,000 women, greatly surpassing yields for supplemental digital breast tomosynthesis (1.25 per 1,000) or supplemental ultrasound (4.1 per 1,000). The...
Expert Point of View: William J. Gradishar, MD
Discussant William J. Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, endorsed Dr. Shafaee’s conclusions, while highlighting caution in interpreting the results. “At first blush, it certainly is...
Aromatase Inhibitors May Decrease Risk of Contralateral Breast Cancer in BRCA Mutation–Positive Patients
Given that BRCA1 and BRCA2 mutation carriers have an estimated 40% to 85% lifetime risk of breast cancer and an increased risk of developing contralateral breast cancer, risk reduction in this population remains essential. According to a study presented at the 2015 Breast Cancer Symposium, use of...
Expert Point of View: William J. Gradishar, MD, FASCO
Discussant of the Neoadjuvant Breast Symphony Trial data, William J. Gradishar, MD, FASCO, Betsy Bramsen Professor of Breast Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, underscored the importance of identifying patients in a more precise and...
Functional Subtyping With 80-Gene Assay Identifies Distinct Triple-Positive Subtypes in Breast Cancer Patients
Molecular categorization of tumors with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) has become a critical component in the diagnosis and treatment of breast cancer, improving outcomes by assigning the most appropriate therapy to specific tumor pathways. According to a...
Expert Point of View: Clifford Hudis, MD
Discussant Clifford Hudis, MD, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York, highlighted the obvious clinical advantages of APF530 over the current standard of care. “If this drug were simply the same in price and availability, why wouldn’t you use it? It’s...
APF530 Superior to Ondansetron in Preventing Chemotherapy-Induced Nausea or Vomiting
As part of a three-drug regimen, APF530 (extended-release formulation of granisetron) has become the first 5-HT3 (5-hydroxytryptamine) receptor antagonist to demonstrate superiority over the standard of care for delayed nausea and vomiting after highly emetogenic chemotherapy. According to the...
Expert Point of View: Clifford Hudis, MD, Shanu Modi, MD, and Richard Gelber, PhD
Discussant Clifford Hudis, MD, Chief of Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York, highlighted neratinib’s benefits while also advocating caution in interpreting the results due to incomplete data, the serious side effect of diarrhea, and the potentially...
Neratinib Improves Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer
Patients with early-stage HER2-positive breast cancer who received neratinib as extended adjuvant therapy demonstrated improved invasive disease–free survival, with an absolute benefit of 2.3% at 2 years.1 However, these results of the ExteNET trial, previously presented at the 2015 ASCO Annual...
Expert Point of View: Charles E. Geyer, Jr, MD, FACP
Discussant Charles E. Geyer, Jr, MD, FACP, Associate Director for Clinical Research at Virginia Commonwealth University Massey Cancer Center in Richmond, Virginia, singled out the power of this study’s dataset. “In 2002,” he said, “the Institute of Medicine named NSQIP [National Surgical Quality...
Neoadjuvant Chemotherapy Appears to Have No Effect on Short-Term Outcomes in Breast Cancer Surgery
Patients who received neoadjuvant chemotherapy within 30 days prior to breast cancer surgery did not appear to be at increased risk for overall postoperative complications, according to a study presented at the 2015 Breast Cancer Symposium.1 “Although on unadjusted analysis there were more...
Expert Point of View: Charles E. Geyer, Jr, MD, FACP
Although the study clearly showed statistically significant differences, discussant Charles E. Geyer, Jr, MD, FACP, Associate Director of Clinical Research at the Massey Cancer Center in Richmond, Virginia, indicated that it’s unclear whether these are “clinically relevant differences,” adding...
Tumor Profiling of Breast Tumors in Older Patients Reveals Differences From Those of Younger Patients
Using multiplatform profiling, researchers have identified potentially targetable biomarker aberrations in a large cohort of geriatric breast tumors.1 According to the study, presented at the 2015 Breast Cancer Symposium, these data may help researchers to design clinical trials focusing on...
